uploads///Revenues

Roche’s Financial Overview in August

By

Aug. 23 2018, Published 10:56 a.m. ET

Revenue trends

Roche (RHHBY) reported revenues of 28.1 billion Swiss francs in the first half of 2018 compared to 26.3 billion Swiss francs in the first half of 2017, reflecting ~7.0% YoY (year-over-year) growth.

In the second quarter, Roche reported revenues of 14.5 billion Swiss francs compared to 13.4 billion Swiss francs in the second quarter of 2017, reflecting ~8.0% YoY growth.

In the first half, Roche’s Pharmaceuticals division and Diagnostics division reported revenues of 21.8 billion Swiss francs and 5.8 billion Swiss francs, respectively, reflecting ~6.0% and ~8.0% YoY growth. In the second quarter, Roche’s Pharmaceuticals division and Diagnostics division reported revenues of 11.2 billion Swiss francs and 3.4 billion Swiss francs, respectively, reflecting ~8.0% and 10.0% YoY growth.

In the United States, Europe, and Japan, Roche’s Pharmaceuticals division reported second-quarter revenues of 5.9 billion Swiss francs, 2.2 billion Swiss francs, and 930.0 million Swiss francs, respectively.

In the second quarter of 2017, these divisions reported revenues of 5.1 billion Swiss francs, 2.3 billion Swiss francs, and 915.0 million Swiss francs, representing ~15.0% growth, a 1.0% decline, and 2.0% growth, respectively, on a YoY basis.

In the first half, Roche reported an operating profit of 9.8 billion Swiss francs compared to 7.8 billion Swiss francs in the second quarter of 2017, which reflected ~26.0% YoY growth.

Roche reported net income of 7.5 billion Swiss francs in the first half, reflecting ~35.0% YoY growth.

Article continues below advertisement

Expense trends

In the first half, Roche reported its cost of sales of 8.0 billion Swiss francs compared to 8.8 billion Swiss francs in the first half of 2017, which reflected an ~8.0% YoY decline.

In the first half, Roche reported M&D (marketing and distribution), R&D (research and development), and G&A (general and administration) expenses of 4.6 billion Swiss francs, 5.6 billion Swiss francs, and 1.5 billion Swiss francs, respectively. In comparison, it reported M&D, R&D, and G&A expenses of 4.5 billion Swiss francs, 5.6 billion Swiss francs, and 903.0 million Swiss francs in the first half of 2017.

Among Roche’s peers in the biopharmaceuticals market, Novartis (NVS), Johnson & Johnson (JNJ), and  Pfizer (PFE) reported revenues of $13.2 billion, $20.8 billion, and $13.5 billion, respectively, in the second quarter.

Advertisement

More From Market Realist